ProCE Banner Activity

CE

Iron Deficiency: Managed Care Considerations for Optimizing Evidence-Based and Cost-Effective Use of IV Iron Replacement Therapies

Multimedia

This on-demand webcast from 2022 AMCP Nexus provides expert perspectives on the role of IV iron replacement for iron deficiency anemia associated with heart failure, chronic kidney disease, and inflammatory bowel disease with a focus on how IV iron affects heathcare resource utilizaton.

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: December 19, 2022

Expiration: December 18, 2023

No longer available for credit.

Share

Faculty

YuQian Liu

YuQian Liu, PharmD

Senior Director
Specialty Clinical Solutions
Magellan Rx Management
Middletown, Rhode Island

Branden D. Nemecek

Branden D. Nemecek, PharmD, BCPS

Associate Professor
Pharmacy Practice
Duquesne University
Clinical Pharmacist
University of Pittsburgh Medical Center Mercy Hospital
Pittsburgh, Pennsylvania

Provided by

ProCE Banner

Supporters

This activity is supported by an educational grant from

American Regent

Target Audience

This activity is intended for pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with iron deficiency, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize the etiology, pathophysiology, and impact of iron deficiency in common comorbidities such as HF, CKD, and IBD

  • Discuss efficacy and safety data regarding IV iron replacement therapies for the treatment of iron deficiency in concomitant chronic conditions, as well as recommended dosing and appropriate implementation of these agents

  • Determine strategies to optimize access to appropriate patient-centered therapies and mitigate financial burdens to improve the management of iron deficiency and promote efficient healthcare resource utilization 

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

 

 

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

 

YuQian Liu, PharmD, has no relevant financial relationships to disclose.

Branden D. Nemecek, PharmD, BCPS, has no relevant financial relationships to disclose.

The planners and content peer reviewers from ProCE, LLC do not have any relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

 

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-203-H01-P has been assigned to this home study application-based activity. This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Additional Information

Program Medium

This program has been made available online.